Results 261 to 270 of about 70,621 (279)

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Cancer Cell, 2004
Keng-Hsueh Lan, Ming Tan, Gabriel N Hortobagyi   +2 more
exaly  

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine, 2005
Nancy E Davidson, Soonmyung Paik, Sandra M Swain   +2 more
exaly  

Trastuzumab/trastuzumab-deruxtecan

Reactions Weekly
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2017
  +4 more sources

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Lancet, The, 2007
Ian Smith, Andrea Feyereislova, Gabriella Mariani   +2 more
exaly  

Trastuzumab/trastuzumab-emtansine

Reactions Weekly
openaire   +1 more source

Trastuzumab

Reactions Weekly
  +4 more sources

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Lancet, The, 2019
Xavier Pivot, Pierre Fumoleau, Laurence Venat-Bouvet   +2 more
exaly  

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

New England Journal of Medicine, 2005
Michael Untch, Ian Smith, Luca Gianni
exaly  

Emtansine/pertuzumab/trastuzumab/trastuzumab

Reactions Weekly
openaire   +1 more source